Sydney Lupkin
Stories
-
Health
Federal Supply Deal For COVID-19 Antibody Treatment Lacks Some Customary Protections
To boost the supply of Regeneron's antibody therapy for COVID-19, the federal government entered into a $450 million supply contract. Details of the deal show some safeguards are missing.
-
Health
After Months of Questions, Key Operation Warp Speed Adviser's Contract Emerges
Drug industry veteran Moncef Slaoui is a key figure in Operation Warp Speed push to develop COVID-19 coronavirus vaccines. His employment terms raised concerns about potential conflicts of interest.
-
Health
Call For Administration's COVID-19 Vaccine Contracts To Be Disclosed
Members of Congress and advocacy groups say Operation Warp Speed should release its contracts with vaccine makers after NPR reporting found the terms of many aren't public.
-
National
9 Companies Pledge Not To Submit Coronavirus Vaccine To FDA Until It's Proved Safe
To reassure the public, nine companies issued a joint statement Tuesday saying they won't seek government approval for their coronavirus vaccines until full safety and effectiveness data are in hand.
-
Business
How Feds Decide On Remdesivir Shipments To States Remains Mysterious
The federal government is in charge of distributing one of the few treatment options for COVID-19: the antiviral drug remdesivir. But how are decisions made about which states need it most?
-
Health
Prices For COVID-19 Vaccines Are Starting To Come Into Focus
Moderna, one of the leading horses in the coronavirus vaccine race, has already made deals at between $32 and $37 a dose for some foreign countries. The U.S. price is expected to be lower.
-
Health
U.S. Reaches $2.1 Billion Deal With Sanofi, GlaxoSmithKline For COVID-19 Vaccine Push
This is the sixth vaccine candidate to join Operation Warp Speed's portfolio, and the largest vaccine deal to date.
-
Health
U.S. To Get 100 Million Doses of Pfizer Coronavirus Vaccine In $1.95 Billion Deal
If the company's vaccine candidate pans out, Americans can receive it for free under the deal. The arrangement is part of the U.S. government's push to have a vaccine widely available by January.
-
Health
Early Oxford-AstraZeneca Coronavirus Vaccine Data 'Encouraging,' Scientists Say
Testing in more than 1,000 people found the vaccine spurred an immune response and had no severe side effects. Larger trials are underway.
-
Health
'Meaningless' FDA Certificates Are Used To Tout Dubious Face Masks
Companies that made hats, socks and teddy bears have started producing surgical masks to protect people from COVID-19. Some sellers exaggerate their standing with the Food and Drug Administration.